Plectin-Targeted Liposomes for PARP Inhibitor Delivery
Solution Overview
Problem
Patients with BRCA1/2 mutations undergoing PARP inhibitor treatment for ovarian cancer often experience adverse side effects due to off-target effects, such as neutropenia and thrombocytopenia, and there is a need for targeted delivery methods to enhance the therapeutic index of these drugs.
Innovation Solution
Development of Plectin Targeted Peptide (PTP) conjugated nanoparticles, specifically liposomes, that encapsulate PARP inhibitors like AZ7379, allowing for targeted delivery to cancer cells expressing plectin, thereby enhancing PARP inhibition and reducing tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP inhibitors are administered systemically at doses necessary to achieve PARP inhibition, then therapeutic effect is improved, but adverse side effects such as neutropenia and thrombocytopenia worsen
Solution Approach 1:
The patent uses targeted nanoparticles as an intermediary carrier to deliver PARP inhibitors specifically to cancer cells expressing plectin. The nanoparticle mediates between the drug and the target cell, enabling selective delivery that achieves therapeutic effect while sparing healthy cells from toxic exposure
Solution Approach 2:
The patent applies local quality by concentrating the PARP inhibitor delivery specifically at cancer cell locations where plectin is expressed. The targeted nanoparticles accumulate at the tumor site and release the drug locally, creating high drug concentration where needed while maintaining low systemic levels to avoid side effects
2Reliability
If PARP inhibitors are administered at high doses to overcome resistance, then efficacy against resistant tumors is improved, but off-target effects such as myelodysplastic syndrome worsen
Solution Approach 1:
Targeted nanoparticles serve as a mediator that enables high local concentration of PARP inhibitors at tumor sites without requiring high systemic doses. The nanoparticle carrier protects healthy tissues from exposure while delivering therapeutic levels directly to cancer cells, even those with resistance mechanisms
Solution Approach 2:
The patent exploits the cancer cells' own plectin expression as a self-service targeting mechanism. The endogenous plectin on cancer cell surfaces automatically binds the targeted nanoparticles, enabling the cancer cells to essentially deliver the drug to themselves without requiring external targeting systems
Data Source
AI summary
The present invention provides compositions and methods to treat cancer.